A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland.
Locati
L D
LD
Quattrone
P
P
Bossi
P
P
Marchianò
A V
AV
Cantù
G
G
Licitra
L
L
D000230:Adenocarcinoma / Q000532:radiotherapy / Q000601:surgery; D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage*; D000813:Anilides / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology*; D009570:Nitriles; D010306:Parotid Gland / Q000601:surgery; D010307:Parotid Neoplasms / Q000532:radiotherapy / Q000601:surgery; D018714:Radiotherapy, Adjuvant; D011944:Receptors, Androgen / Q000187:drug effects; D018570:Risk Assessment; D012883:Skin Ulcer / Q000188:drug therapy / Q000473:pathology; D014105:Tosyl Compounds; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000008:administration & dosage*
D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D011944:Receptors, Androgen; D014105:Tosyl Compounds; D017329:Triptorelin Pamoate; C053541:bicalutamide